The University of Colorado Anschutz received a $120 million DARPA award to evaluate emerging technologies and novel therapeutics for severe hemorrhage over three years. This makes CU Anschutz a key site for DARPA's RAPIID program, which aims to improve treatment options for severe bleeding through blood-like products and diagnostics. The program will test up to 11 products, helping determine which are safe and effective enough for clinical trials and FDA approval. The initiative could benefit trauma patients, military personnel, and others facing life-threatening bleeding, while also addressing blood supply challenges in the U.S.
The University of Colorado Anschutz's recent $120 million federal research award sets a significant context for innovation in severe hemorrhage treatments. For readers following the health sector, here is Pluang's market snapshot as of Oct 13, 2026 22:41 WIB: out of 128 priced US health stocks, 30 rose and 98 fell. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.39 with 76% sell order activity, Sana Biotechnology Inc (SANA) at USD 2.47 with 89% buy order activity, and Johnson & Johnson (JNJ) at USD 248.70 with 84% sell order activity.
Wells Fargo reported third-quarter 2026 earnings per share (EPS) of $1.87, surpassing analyst estimates of $1.85, while revenue came in at $21.87 billion, below the expected $22.31 billion. The bank saw a 13% rise in EPS and a 6% increase in net inco...
Bank of America is set to report Q3 earnings with analysts expecting $1.10 per share and $30.54 billion in revenue, up from last year. CEO Brian Moynihan forecasts a 10% drop in investment banking fees and flat trading revenue. The bank's stock has f...
Reach Security secured over $50 million in Series B funding led by Top Tier Capital Partners to enhance its AI-driven cybersecurity platform. The company’s technology autonomously identifies and closes security gaps faster than AI-powered attackers c...
Rexel Développement SAS announced the total number of its shares and voting rights as of October 1, 2026. The company holds 311,385,744 shares, with a theoretical voting right count matching this number. However, the exercisable voting rights, exclud...
Rexel Développement SAS announced the total number of shares and voting rights as of October 1, 2026. The company holds 311,385,744 shares in total, with 311,385,744 theoretical voting rights including treasury shares without voting rights. The numbe...
